Jung, S. C., Schlenk, R. F., Hackenbruch, C., Roldan Pinzon, S. S. L., Bitzer, M., Pflügler, M., . . . Salih, H. R. (2024). Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3). Frontiers in oncology, 14, . https://doi.org/10.3389/fonc.2024.1351901
Chicago-Zitierstil (17. Ausg.)Jung, Susanne Claudia, et al. "Protocol of a First-in-human Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the Bispecific CD276xCD3 Antibody CC-3 in Patients with Colorectal Cancer (CoRe_CC-3)." Frontiers in Oncology 14 (2024). https://doi.org/10.3389/fonc.2024.1351901.
MLA-Zitierstil (9. Ausg.)Jung, Susanne Claudia, et al. "Protocol of a First-in-human Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the Bispecific CD276xCD3 Antibody CC-3 in Patients with Colorectal Cancer (CoRe_CC-3)." Frontiers in Oncology, vol. 14, 2024, https://doi.org/10.3389/fonc.2024.1351901.